Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Posters

Search Title by author or title

Femtosecond laser-assisted sutureless anterior lamellar keratoplasty (FALK): two years follow-up

Poster Details

First Author: F.Luengo Gimeno ARGENTINA

Co Author(s):    F. Arasanz                    

Abstract Details

Purpose:

To report the technique and visual outcomes of femtosecond laser�â�€�“assisted sutureless anterior lamellar keratoplasty (FALK) for anterior corneal pathology.

Setting:

Arasanz Laser Vision, Buenos Aires, Argentina.

Methods:

Retrospective, noncomparative, interventional case series of 3 eyes from 3 patients that underwent Femtosecond Laser�â�€�“Assisted Sutureless Anterior Lamellar Keratoplasty (FALK) for anterior corneal pathology between 2014 and 2016 at a single institution.�Â�  Stromal opacities were measured with the IvueSD OCT (Optovue Inc, Fremont, CA) and Vysante (Carl Zeiss Meditec). The Femtosecond laser (iFS�Â�®�Â� Advanced Femtosecond Laser, Abbott Medical Optics) was used for donor and recipient The main outcome measures were lenticule pachymetry, UCVA, BSCVA, endothelial cell loss and aberrometry at 1, 3, 6, 12�Â� and 24 months postoperatively. Complications including graft dislocation and graft failure were recorded.

Results:

No intraoperative complications were found. At 2 years of follow up, BSCVA improved by >5 lines in all eyes (20/80 preoperatively, 20/25 at 2 years postoperatively (POP), p=0,05), and UCVA improved by >2 lines in all eyes. One graft required to be sutured because of graft dehiscence on day 2 POP. All grafts and interphases were clear during all the follow up. The mean endothelial cell loss was <5%, similar to the contralateral non-treated eye. No high order aberrations were found.

Conclusions:

Femtosecond laser�â�€�“assisted sutureless anterior lamellar keratoplasty is a safe and efficient procedure that improve UCVA and BSCVA in patients with anterior corneal opacities. However, further investigation is warranted in order to validate these findings.

Financial Disclosure:

NONE

Back to Poster listing